Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Opal

Showing results (71-80 of 168) with videos related to

Pageof 17
Sort By:
Critical Care (London, England)|July 17, 2014
The dysfunctional host response to influenza A H7N9: a potential treatment option?Steven M Opal, David S Fedson
Virulence|August 5, 2014
Middle East respiratory syndrome (MERS): a new zoonotic viral pneumoniaCheston B Cunha, Steven M Opal
Intensive Care Medicine|February 15, 2017
Should all septic patients be given systemic anticoagulation? NoTom van der Poll, Steven M Opal
Expert Review of Anti-Infective Therapy|October 28, 2011
Immunomodulatory therapy for sepsis: an updateEirini Christaki, Panagiota Anyfanti, Steven M Opal
Annals of Translational Medicine|October 8, 2016
The role of genetics and antibodies in sepsisEvangelos J Giamarellos-Bourboulis, Steven M Opal
Lancet (London, England)|October 12, 2020
Steroids for sepsis and ARDS: this eternal controversy remains with COVID-19Jean Carlet, Didier Payen, Steven M Opal
Lancet (London, England)|November 3, 2009
Pathogenesis, treatment, and prevention of pneumococcal pneumoniaTom van der Poll, Steven M Opal
Current Opinion in Infectious Diseases|February 14, 2012
Receptor for advanced glycation end products in bacterial infection: is there a role for immune modulation of receptor for advanced glycation end products in the treatment of sepsis?Eirini Christaki, Nikolaos Lazaridis, Steven M Opal
The Lancet. Infectious Diseases|December 8, 2007
Host-pathogen interactions in sepsisTom van der Poll, Steven M Opal
Virulence|August 27, 2013
A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogensXavier Wittebole, Sophie De Roock, Steven M Opal
Pageof 17

Showing results (71-80 of 168) with videos related to

Sort By:
Pageof 17
Critical Care (London, England)|July 17, 2014
The dysfunctional host response to influenza A H7N9: a potential treatment option?Steven M Opal, David S Fedson
Virulence|August 5, 2014
Middle East respiratory syndrome (MERS): a new zoonotic viral pneumoniaCheston B Cunha, Steven M Opal
Intensive Care Medicine|February 15, 2017
Should all septic patients be given systemic anticoagulation? NoTom van der Poll, Steven M Opal
Expert Review of Anti-Infective Therapy|October 28, 2011
Immunomodulatory therapy for sepsis: an updateEirini Christaki, Panagiota Anyfanti, Steven M Opal
Annals of Translational Medicine|October 8, 2016
The role of genetics and antibodies in sepsisEvangelos J Giamarellos-Bourboulis, Steven M Opal
Lancet (London, England)|October 12, 2020
Steroids for sepsis and ARDS: this eternal controversy remains with COVID-19Jean Carlet, Didier Payen, Steven M Opal
Lancet (London, England)|November 3, 2009
Pathogenesis, treatment, and prevention of pneumococcal pneumoniaTom van der Poll, Steven M Opal
Current Opinion in Infectious Diseases|February 14, 2012
Receptor for advanced glycation end products in bacterial infection: is there a role for immune modulation of receptor for advanced glycation end products in the treatment of sepsis?Eirini Christaki, Nikolaos Lazaridis, Steven M Opal
The Lancet. Infectious Diseases|December 8, 2007
Host-pathogen interactions in sepsisTom van der Poll, Steven M Opal
Virulence|August 27, 2013
A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogensXavier Wittebole, Sophie De Roock, Steven M Opal
Pageof 17